Sabrina Serani

Articles

Sacituzumab Govitecan Plus Pembrolizumab Yields Predictable, Manageable Safety Profile in TNBC

December 12th 2025

Sacituzumab govitecan combined with pembrolizumab showed a manageable safety profile with lower TEAE discontinuation rates in TNBC.

Menopausal HRT Does Not Influence Breast Cancer Risk in Women Harboring BRCA Variants

December 12th 2025

Menopausal hormone replacement therapy was not associated with an increased risk of breast cancer in women with BRCA mutations.

Adjuvant Aromatase Inhibition Is Associated With Improved DFS, TTDR in HR+/HER2+ Breast Cancer

December 10th 2025

Adjuvant AI therapy improved DFS and TTDR vs a SERM in patients with hormone receptor–positive, HER2-positive early breast cancer.

Pirtobrutinib Yields Improved Efficacy Over BR in First-Line CLL/SLL

December 9th 2025

Pitrobrutinib monotherapy showed significant efficacy improvements in first-line CLL/SLL compared with BR treatments.

Zanubrutinib Plus Venetoclax Displays Long-Term PFS Benefit in Untreated CLL/SLL

December 9th 2025

Zanubrutinib plus venetoclax maintained a 36-month PFS rate of 87% (95% CI, 78.6%–92.4%) in treatment-naive CLL/SLL.

MaaT013 Shows Tolerability, Early Efficacy in Refractory Acute GVHD With GI Involvement

December 8th 2025

The microbiota-based therapy had a favorable safety profile and demonstrated response-driven prolongation of survival in this patient population.

Linvoseltamab Generates Responses in Newly Diagnosed Myeloma

December 8th 2025

Linvoseltamab monotherapy produced responses and was safe in newly diagnosed multiple myeloma.

Gintemetostat Shows Early Activity and Manageable Safety in Triple-Class Refractory Multiple Myeloma

December 7th 2025

Gintemetostat demonstrates efficacy and safety in heavily pretreated multiple myeloma patients, paving the way for future combination therapies.

Lisaftoclax Displays Activity in R/R CLL/SLL

December 6th 2025

Lisaftoclax demonstrated efficacy and safety for the treatment of patients with relapsed/refractory CLL/SLL.

Early Use of Cilta-Cel Is Linked to Stronger Outcomes Due to Immune Fitness in R/R Myeloma

December 6th 2025

Administering cilta-cel earlier in treatment improves clinical outcomes, with superior PFS and OS rates compared to later intervention.

Beyond the Genome: Exploring New Frontiers in NSCLC Management

November 15th 2025

Soo-Ryum (Stewart) Yang, MD, discusses biomarkers for ADCs, the actionability of tumor suppressor genes, and the advent of computational pathology.

Trastuzumab Rezetecan Displays PFS Benefit Vs Pyrotinib Plus Capecitabine in Pretreated HER2+ Breast Cancer

October 23rd 2025

Trastuzumab rezetecan reduced the risk of disease progression or death by 78% vs pyrotinib plus capecitabine in pretreatedHER2+ advanced breast cancer,

Atezolizumab Plus BCG Does Not Improve EFS Vs BCG Alone in BCG-Naive NMIBC

October 22nd 2025

Atezolizumab plus BCG did not extend EFS vs BCG alone in BCG-naive, high-risk non–muscle invasive bladder cancer.

Raludotatug Deruxtecan Demonstrates Promising Efficacy, Safety in Platinum-Resistant Ovarian Cancer

October 20th 2025

Raludotatug deruxtecan demonstrates antitumor activity and manageable safety in platinum-resistant ovarian cancer.

Durvalumab Plus Chemo Yields Inconclusive Results in Advanced Pleural Mesothelioma

October 19th 2025

Durvalumab in combination with chemotherapy produced outcomes consistent with prior studies in patients with advanced pleural mesothelioma.

Pembrolizumab/Lenvatinib Combo Is Active, Safe in Uveal Melanoma

October 19th 2025

Pembrolizumab plus lenvatinib was safe and active in HLA-A*02:01–negative and –positive uveal melanoma.

177-Lu-edotretide Prolongs PFS Compared With Everolimus in Grade 1/2 GEP-NETs

October 18th 2025

177-Lu-edotretide significantly improved survival outcomes vs everolimus for the treatment of patients with grade 1/2 GEP-NETs.

Darolutamide Plus ADT Confers HRQOL Benefits in Metastatic Hormone-Sensitive Prostate Cancer

June 3rd 2025

A PRO analysis showed that darolutamide plus ADT improved HRQOL outcomes vs placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer.

Rusfertide Shines as New Treatment Option in Polycythemia Vera

June 2nd 2025

In the VERIFY study, rusfertide significantly improved clinical responses vs placebo in polycythemia vera, offering a potential new therapy.

Adjuvant Nivolumab Generates Long-Term DFS Benefit in Resected Esophageal/GEJ Cancer

June 1st 2025

Adjuvant nivolumab generated durable DFS and DMFS outcomes in resectable esophageal or GEJ cancer.